SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
Securities Exchange Act of 1934
FEBRUARY 7, 1997
Date of Report (Date of earliest event reported)
COLUMBIA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 1-10352 59-2758596
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
2665 SOUTH BAYSHORE DRIVE
MIAMI, FLORIDA 33133
(305) 860-1670
(Address, including zip code and telephone number,
including area code, of registrant's principal executive offices)
<PAGE>
ITEM 5. OTHER EVENTS.
On February 7, 1997, the Company received notification from the U.S. Food and
Drug Administration approving the Company's Treatment Protocol under its IND for
the use of Crinone/registered trademark/, vaginally delivered natural
progesterone, in assisted fertility procedures. As a result, through leads
generated by the Wyeth-Ayerst institutional sales force, Columbia will shortly
begin distributing Crinone to leading infertility clinics throughout the United
States.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
COLUMBIA LABORATORIES, INC.
DATE: February 12, 1997 By: /s/ MARGARET J. ROELL
------------------------------------------
Margaret J. Roell
Vice President-Finance and Administration
Chief Financial Officer
